Online inquiry

IVTScrip™ mRNA-Anti-IL17A&IL17F, CDP4940(Cap 0, 2-Thio-UTP, 120 nt-poly(A))   (CAT#: GTTS-WQ5523MR)

This product GTTS-WQ5523MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 0 & 2-Thio-UTP. It ecodes the monoclonal antibody that targets IL17A&IL17F gene. The antibody can be applied in Psoriasis research.
Specifications
Product type mRNA
Modified bases 2-Thio-UTP
5' Cap Cap 0
Species Humanized
RefSeq NM_002190.3; NM_052872.4
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 3605; 112744
UniProt ID Q16552; Q96PD4
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-IL17A&IL17F, CDP4940(Cap 0, 2-Thio-UTP, 120 nt-poly(A)) (GTTS-WQ5523MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ10445MR IVTScrip™ mRNA-Anti-MSTN, LY-2495655(Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA LY-2495655
GTTS-WQ10723MR IVTScrip™ mRNA-Anti-FCGRT, M-281(Cap 0, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA M-281
GTTS-WQ2962MR IVTScrip™ mRNA-Anti-PDCD1, ANB-011(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA ANB-011
GTTS-WQ14156MR IVTScrip™ mRNA-Anti-IL6R, aIL6R88(Cap 1, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA aIL6R88
GTTS-WQ11059MR IVTScrip™ mRNA-Anti-EGFR&LGR5, MCLA-158(Cap 0, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA MCLA-158
GTTS-WQ434MR IVTScrip™ mRNA-Anti-AMHR2, 3C23K(Cap 1, 2-Thio-UTP, 30 nt-poly(A)) mRNA 3C23K
GTTS-WQ10428MR IVTScrip™ mRNA-Anti-MSTN, LY-2495655(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA LY-2495655
GTTS-WQ12837MR IVTScrip™ mRNA-Anti-FZD10, ONC-005(Cap 0, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA ONC-005
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW